Merck
CN

SML2259

Sigma-Aldrich

拉帕替尼

≥98% (HPLC)

登录查看公司和协议定价

别名:
拉帕替尼, GD 2016, GSK 572016, GW-572016, GW572016, N-(3-氯-4-((3-氟苯基)甲氧基)苯基)-6-(5-((2-甲基磺酰基乙基氨基)甲基)-2-呋喃基)喹唑啉-4-胺, N-(3-氯-4-((3-氟苯基)甲氧基)苯基)-6-(5-((((2-(甲基磺酰基)乙基)氨基)甲基)-2-呋喃基)-4-喹唑啉胺
经验公式(希尔记法):
C29H26ClFN4O4S
分子量:
581.06
MDL编号:
NACRES:
NA.77

检测方案

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

2-8°C

SMILES字符串

CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O

InChI

1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

InChI key

BCFGMOOMADDAQU-UHFFFAOYSA-N

基因信息

正在寻找类似产品? Visit 产品对比指南

生化/生理作用

拉帕替尼(lapatinb)是针对表皮生长因子受体(EGFR/ErbB1)和人表皮生长因子受体2(HER2/ErbB2)的双酪氨酸激酶抑制剂。它与三磷酸腺苷(ATP)竞争酪氨酸激酶结构域上的结合位点。已有研究表明拉帕替尼参与乳腺、肺、外阴、胃和头颈癌等多种人癌细胞中的体外生长抑制和凋亡诱导。

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Aquatic Chronic 4 - Eye Irrit. 2 - Lact.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

为方便起见,与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码?

在网站页面上,产品编号会附带包装尺寸/数量一起显示(例如:T1503-25G)。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题?欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ (Lot或Batch)字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等,请输入去除前两位字母的批号:09019TO。

  • 如果您查询到的批号含有填充代码(例如05427ES-021),请输入去除填充代码-021的批号:05427ES。

  • 如果您查询到的批号含有填充代码(例如 STBB0728K9),请输入去除填充代码K9的批号:STBB0728。

未找到您寻找的产品?

部分情况下,可能未在线提供COA。如果搜索不到COA,可在线索取。

索取COA

Lapatinib in breast cancer
Bilancia D, et al.
Annals of Oncology, 18, vi26-vi30 (2007)
Sharad Verma et al.
PloS one, 13(2), e0190942-e0190942 (2018-02-02)
HER-2 belongs to the human epidermal growth factor receptor (HER) family. Via different signal transduction pathways, HER-2 regulates normal cell proliferation, survival, and differentiation. Recently, it was reported that MCF10A, BT474, and MDA-MB-231 cells bearing the HER2 K753E mutation were
Dongwei Zhang et al.
Molecular cancer therapeutics, 7(7), 1846-1850 (2008-07-23)
Epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2/neu), members of the ErbB receptor tyrosine kinase family, are frequently overexpressed in breast cancer and are known to drive tumor growth and progression, making them promising targets for cancer therapy. Lapatinib is
Richard M Tehan et al.
Journal of natural products, 85(5), 1363-1373 (2022-05-03)
The genome of entomopathogenic fungus Tolypocladium inflatum Gams encodes 43 putative biosynthetic gene clusters for specialized metabolites, although genotype-phenotype linkages have been reported only for the cyclosporins and fumonisins. T. inflatum was cultured in defined minimal media, supplemented with or
Egle Avizienyte et al.
The Biochemical journal, 415(2), 197-206 (2008-07-01)
Recent clinical data indicates that the emergence of mutant drug-resistant kinase alleles may be particularly relevant for targeted kinase inhibitors. In order to explore how different classes of targeted therapies impact upon resistance mutations, we performed EGFR (epidermal-growth-factor receptor) resistance

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门